The Gout Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

“Gout Pipeline Insight, 2023“ report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Gout Market.

Some of the key takeaways from the Gout Pipeline Report:

• Companies across the globe are diligently working toward developing novel Gout treatment therapies with a considerable amount of success over the years. 
• Gout companies working in the treatment market are TaiwanJ Pharmaceuticals, Nippon Chemiphar, HemoShear Horizon Therapeutics, Protalix BioTherapeutics, Horizon Therapeutics plc, Arthrosi Therapeutics, Dyve Biosciences, LG Chem, Jiangsu Hengrui Medicine Co., Selecta Biosciences Inc, InventisBio Co., Ltd, Allena Pharmaceuticals, Olatec Therapeutics LLC, Shanton Pharma Co., Ltd., LG Chem, and others, are developing therapies for the Gout treatment 

• Emerging Gout therapies in the different phases of clinical trials are- TJC-0434, NC-2700, Research Program, NC-2500, PRX-115, HZN-457, AR-882, DYV700, LC350189, SHR-4640, SEL-212, D-0120 + Allopurinol, ALLN-346, Dapansutrile, SAP001, Tigulixostat, and others are expected to have a significant impact on the Gout market in the coming years. 
• In March 2023, Selecta Biosciences, Inc. revealed favorable outcomes from the Phase 3 DISSOLVE I & II trials, comparing SEL-212 against a placebo. SEL-212 aims to address chronic refractory gout.
• In September 2022, Jiangsu HengRui Medicine Co., Ltd.’s SHR4640 underwent a phase 3 clinical trial with the aim of reducing serum uric acid levels in patients.
• Novel drugs such as LG Chem’s LC350189, Shanton Pharma’s SAP-001, and InventisBio’s D-0120 are currently undergoing phase 2 trials, intensifying competition among companies striving to introduce these products to the market.
• In November 2020, Selecta Biosciences has commenced one of two randomized, double-blind, placebo-controlled trials in parallel arms. These trials aim to evaluate the safety and effectiveness of two distinct dosage levels of SEL-212 in comparison to a placebo.
• Both SEL-212 and pegloticase demonstrated positive safety profiles and good tolerance levels: The study reported no fatalities. No significant differences in serious Treatment Emergent Adverse Events (TEAEs), treatment-related serious TEAEs, or infusion reactions were observed between the two groups.

Gout Overview

An extremely painful type of inflammatory arthritis that is common is gout. Usually, it only affects one joint at a time, most commonly the big toe joint. Periods of increased symptom severity are referred to as flares, and periods with no symptoms are referred to as remission.

Get a Free Sample PDF Report to know more about Gout Pipeline Therapeutic Assessment-

https://www.delveinsight.com/report-store/gouty-arthritis-gout-pipeline-insight

Emerging Gout Drugs Under Different Phases of Clinical Development Include:

• TJC-0434: TaiwanJ Pharmaceuticals
• NC-2700: Nippon Chemiphar
• Research Program: HemoShear Horizon Therapeutics plc
• NC-2500: Nippon Chemiphar
• PRX-115: Protalix BioTherapeutics
• HZN-457: Horizon Therapeutics plc
• AR-882: Arthrosi Therapeutics
• DYV700: Dyve Biosciences
• LC350189: LG Chem
• SHR-4640: Jiangsu Hengrui Medicine Co.
• SEL-212: Selecta Biosciences Inc
• D-0120 + Allopurinol: InventisBio Co., Ltd
• ALLN-346: Allena Pharmaceuticals
• Dapansutrile: Olatec Therapeutics LLC
• SAP001: Shanton Pharma Co., Ltd.
• Tigulixostat: LG Chem

Gout Route of Administration

Gout pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as 

• Intravenous
• Oral
• Parenteral
• Subcutaneous
• Topical
• Molecule Type

Gout Molecule Type

Gout Products have been categorized under various Molecule types, such as

• Protein
• Small interfering RNA
• Small molecule
• Product Type

Gout Pipeline Therapeutics Assessment

• Gout Assessment by Product Type
• Gout By Stage and Product Type
• Gout Assessment by Route of Administration
• Gout By Stage and Route of Administration
• Gout Assessment by Molecule Type
• Gout by Stage and Molecule Type

DelveInsight’s Gout Report covers around 40+ products under different phases of clinical development like

• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I)
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Further Gout product details are provided in the report. Download the Gout pipeline report to learn more about the emerging Gout therapies

Some of the key companies in the Gout Therapeutics Market include:

Key companies developing therapies for Gout are – Jiangsu Hengrui Medicine, Selecta Biosciences, LG Chem, Shanton Pharma, TWi Biotechnology, Olatec Therapeutics, Allena Pharmaceuticals, JW Pharmaceutical, Revive Therapeutics, Hinova pharmaceuticals, Arthrosi Therapeutics, Dyve Biosciences, Jiangsu Atom Bioscience and Pharmaceutical, Swedish Orphan Biovitrum, Allen Pharmaceuticals, Teijin Pharma, AstraZeneca, R-Pharm, InventisBio, Nippon Chemiphar, Sinovent, Shenyang Sunshine Pharmaceutical, Rigel Pharmaceuticals, Chongqing Fochon Pharmaceutical, Alnylam Pharmaceuticals, Enzychem Lifesciences, Arrowhead Pharmaceuticals, Horizon Therapeutics, and others.

Gout Pipeline Analysis:

The Gout pipeline report provides insights into 

• The report provides detailed insights about companies that are developing therapies for the treatment of Gout with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Gout Treatment.
• Gout key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Gout Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. 
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Gout market.

The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

Download Sample PDF Report to know more about Gout drugs and therapies

Gout Pipeline Market Drivers

• The rise in the prevalence of Gout, Novel urate-lowering agents are some of the important factors that are fueling the Gout Market.

Gout Pipeline Market Barriers

• However, gaps in the quality of care, lack of knowledge about guidelines and evidence based gout management, lack of novel therapies in Gout pipeline and other factors are creating obstacles in the Gout Market growth.

Scope of Gout Pipeline Drug Insight    

• Coverage: Global
• Key Gout Companies: TaiwanJ Pharmaceuticals, Nippon Chemiphar, HemoShear Horizon Therapeutics, Protalix BioTherapeutics, Horizon Therapeutics plc, Arthrosi Therapeutics, Dyve Biosciences, LG Chem, Jiangsu Hengrui Medicine Co., Selecta Biosciences Inc, InventisBio Co., Ltd, Allena Pharmaceuticals, Olatec Therapeutics LLC, Shanton Pharma Co., Ltd., LG Chem, and others
• Key Gout Therapies: TJC-0434, NC-2700, Research Program, NC-2500, PRX-115, HZN-457, AR-882, DYV700, LC350189, SHR-4640, SEL-212, D-0120 + Allopurinol, ALLN-346, Dapansutrile, SAP001, Tigulixostat, and others
• Gout Therapeutic Assessment: Gout current marketed and Gout emerging therapies
• Gout Market Dynamics: Gout market drivers and Gout market barriers 

Request for Sample PDF Report for Gout Pipeline Assessment and clinical trials

Table of Contents

1. Gout Report Introduction

2. Gout Executive Summary

3. Gout Overview

4. Gout- Analytical Perspective In-depth Commercial Assessment

5. Gout Pipeline Therapeutics

6. Gout Late Stage Products (Phase II/III)

7. Gout Mid Stage Products (Phase II)

8. Gout Early Stage Products (Phase I)

9. Gout Preclinical Stage Products

10. Gout Therapeutics Assessment

11. Gout Inactive Products

12. Company-University Collaborations (Licensing/Partnering) Analysis

13. Gout Key Companies

14. Gout Key Products

15. Gout Unmet Needs

16 . Gout Market Drivers and Barriers

17. Gout Future Perspectives and Conclusion

18. Gout Analyst Views

19. Appendix

20. About DelveInsight

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV 89107
Country: United States
Website: https://www.delveinsight.com/consulting/due-diligence-services